ChromaDex New Published Phase II Clinical Study Demonstrates That Supplementation With Niagen, Patented Nicotinamide Riboside, Elevates NAD+ Up To Fourfold, Improving Motor Coordination And Eye Movement In Ataxia Telangiectasia Patients

Author: Benzinga Newsdesk | November 15, 2023 09:35am

This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well tolerated

Study highlights

• NR supplementation was well tolerated, with no serious adverse events.
• NR supplementation increased whole blood NAD+ levels up to fourfold.
• Serum levels of AFP, serum alpha-fetoprotein and Nfl, neurofilament light chain, biomarkers of AT progression, remained stable for most participants over two years of NR supplementation, suggesting that NR may slow or delay progression of AT.
• Long-term NR supplementation reduced ataxia symptoms and improved motor coordination, eye movements, and overall neurological functioning:
  • Positive correlations were observed between NR supplementation and improved AT Neurological Examination Toolkit (NEST) total score, eye movements, SARA coordination scores, ICARS coordination scores, and oculomotor scores.
• Biomarkers related to liver and kidney function did not show clinically significant changes during the two-year treatment period, indicating the NR supplementation was safe.
• Long-term blood glucose regulation, measured as HbA1c level, remained stable in all participants.
• NR supplementation did not cause changes in hematological or immunological parameters.

Posted In: CDXC